Logo for NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company Investor Relations Material

Latest events

Logo for NewAmsterdam Pharma Company N.V.

R&D Day 2025

NewAmsterdam Pharma Company
Logo for NewAmsterdam Pharma Company

R&D Day 2025

11 Jun, 2025
Logo for NewAmsterdam Pharma Company

Q1 2025

8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from NewAmsterdam Pharma Company N.V.

Access all reports
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.